Peer-influenced content. Sources you trust. No registration required. This is HCN.
Cancer Therapy Advisor
Explore new horizons in advanced hepatocellular carcinoma treatment with emerging data on lenvatinib and cisplatin’s potential efficacy as a second-line therapy and the promising triple combination therapy showing significant response rates.
Oncology, Medical April 1st 2024
Explore the latest insights from ASCO GU 2024 on first-line treatments for advanced renal cell carcinoma, including the effectiveness of combination therapies and the pressing need to address racial disparities in patient outcomes.
OBR Oncology
Mirvetuximab soravtansine represents a pivotal shift in treating platinum-resistant ovarian cancer, demonstrating not only improved survival outcomes but also a higher response rate compared to standard chemotherapy.
The New England Journal of Medicine
In a recent phase 3 trial, the addition of brentuximab vedotin to standard chemotherapy not only achieved a notable improvement in 3-year event-free survival rates for pediatric Hodgkin’s lymphoma patients but also maintained a comparable safety profile, underscoring the therapeutic potential of targeted treatments in this population.
Hematology/Oncology April 1st 2024
The combination of ribociclib and a nonsteroidal aromatase inhibitor was associated with a notable improvement in invasive disease–free survival rates among early-stage, HR-positive, HER2-negative breast cancer patients, highlighting a significant advancement in the therapeutic landscape of this common malignancy.
British Medical Journal
The study elucidates the substantial impact of exercise, particularly walking or jogging, yoga, and strength training, in alleviating depressive symptoms, advocating for their inclusion as principal treatments in depression care, reflecting a broadened approach to mental health management.
Psychiatry March 19th 2024